ANNUAL REPORT

July 2026

EuropaBio®

The European Association for Bioindustries

Table of Contents

01 About EuropaBio

02 Welcome

03 The Legislative Journey for Biotech

05 Healthcare Biotechnology Council

06 Industrial Biotechnology Council

07 National Associations Council & SME Platform

08 Biomanufacturing Platform

09 EU Projects

10 Communicating Biotechnology

11 EuropaBio in Partnership

12 EuropaBio Members

13 Become Part of EuropaBio

About EuropaBio

Biotechnology for people and planet

EuropaBio is Europe's largest biotechnology industry group, founded in 1996 to represent the interests of the biotechnology ecosystem across sectors. It has the vision to deliver a healthy, sustainable and competitive global Europe through biotechnology innovation.

Its mission is to build EU, national and global frameworks through which this critical technology is delivered across sectors, as the key opinion leader for Europe's biotechnology industrial ecosystem.

EuropaBio Goals

Biotechnology for Europe

To achieve the legislative, regulatory and economic frameworks that empower biotechnology to deliver benefit to citizens, plus growth and resilience for Europe.

Biotechnology in view

To create visibility and recognition for the contribution of biotechnology and biomanufacturing within Europe's societal, environmental and economic ambitions.

Biotechnology in action

To deliver intellectual property, skills, capacity and investment from Europe's innovation excellence.

EuropaBio for Members

Together with its members, EuropaBio is the key opinion leader for European industrial development, competitiveness and global resilience through biotechnology.

It brings Europe's voice of advocacy for biotechnology delivered across sectors, representing the full industrial ecosystem, from start-ups to global actors and the national ecosystems in which they grow.

EuropaBio represents industrial and national stakeholders, including innovative industries for Healthcare and cross-sectoral Industrial Biotechnology, plus the National Associations that champion biotechnology at country level.

Welcome

Dr Claire Skentelbery,
Director General EuropaBio

The EuropaBio 2026 report is published at a moment of intense legislative activity for biotechnology. This has shaped all aspects of our work with members, with outcomes that will determine the EU's future within this critical technology.

The EU Biotech Act Part I landed towards the end of 2025, covering a significant array of biotech applications and frameworks, with Biotech Act Part II expected by the end of 2026.

These two legislations are indicative of the positive landscape for biotechnology in 2026, and EuropaBio has the priority to ensure that ambition, clarity and scope for its application are delivered.

Growing with the times

EuropaBio has continued to grow and evolve its membership, reflecting the ever-expanding sectors into which biotech is applied, organisations involved in its delivery, and its increasingly frontline role for citizens and patients.

Examples include the introduction of expertise from European CROs (with clinical trials in the legislative spotlight) and consumer-facing food industries (with biotechnology increasingly relevant within food legislation). We now represent over 100 direct members, including over 30 national, regional and sectoral associations, which in turn, represent over 6000 innovative SMEs across Europe in all sectors.

Evolving advocacy for biotech as the new EU priority

EuropaBio has also evolved how we address advocacy for biotechnology. As it rises in political significance, with legislative proposals on the table, we need to ensure that.

The Industrial Biotechnology Council now has groups addressing Product policy from Food and Feed, non-Food and Feed and Microorganisms frameworks perspectives, and Industrial Policy, supported by our Public Affairs Working Group. The Healthcare Council has launched an Access and Value working group to support the Regulatory Affairs, Biopharmaceutical Strategy Group and the ATMP/OMP Groups. 2026 has also seen the launch of the Biodefence and Biosecurity Working Group, our second all-Council Working Group which followed the Biotech Act Task Force in 2025.

The growing policy priority of biotechnology plays to the cross sectoral strength of EuropaBio. This enables us to bring depth and breadth to advocacy, not only to achieve policy priorities but also to support our wider association community. The EuropaBio team, Board and Members are working to deliver and we look forward to another productive year for biotechnology.

The Legislative Journey for Biotech

Biotechnology remains central to delivering the European Union's ambitions for competitive, resilient, and sustainable economies and societies. Future-proofing legislative frameworks across healthcare, agri-food, and industrial applications is critical to ensuring that Europe's scientific excellence translates into innovation, growth, and societal benefit.

Now almost mid-way through the current mandate, we can start to see the tangible outcomes for biotechnology from the ambitious opening words from its launch in late 2024. Strategies are starting to yield legislative proposals, including through the series of omnibus legislations to help modernise and simplify regulation, whilst retaining the EU's global standards for evidence-based decision making and safety.

At the centre of this legislative journey sits the EU Biotech Act parts I & II, a generational opportunity to establish a coherent, enabling framework for biotechnology and biomanufacturing. In the previous 12 months, a single legislative proposal evolved into two distinct parts, with Part I delivered in December 2025. Primarily focussed towards health, it makes a substantial advance for clinical trials, recognises the incentives needed for frontier biotech and proposes a framework for collaborative development across Europe. It also touches upon microorganism-driven frameworks and both food-feed and non-food-feed applications, including a welcomed expansion of the EFSA mandate.

During the lifespan of the EuropaBio 2026 report, we will see the progress of Act Part I through the European Parliament. EuropaBio will expand, strengthen and clarify a promising foundation, and ensure that it positions the EU as a leader, especially through its own research and innovator communities. We will also see the adoption of Biotech Act Part II, a testcase legislation for biomanufacturing within the EU.

A key development has been the consolidation of a legislative cluster addressing the full biotech value chain. In healthcare, political agreement on the revision of the EU pharmaceutical framework represents a major overhaul of the system governing medicines, complemented by progress on the Critical Medicines Act to tackle shortages and reinforce supply chains. Ongoing revisions to the In Vitro Diagnostic and Medical Devices Regulations further aim to ensure continued access to innovative technologies. At the same time, these advances highlight the persistent challenge of fragmentation across the Single Market, which continues to limit the full impact of reforms and underscores the need for greater regulatory coherence.

Beyond healthcare, similar dynamics are emerging in industrial biotechnology. The European Commission's Food and Feed Safety Omnibus proposal has addressed long-standing bottlenecks and legal uncertainty, particularly for fermentation-based processes, now increasingly recognised as a strategic platform technology.

Over the past year the National Associations Council, and its key opinion leader SMEs have championed the perspectives of innovators, highlighting the need for improved access to finance, reduced administrative burden, and a more integrated Single Market that supports scale-up and deployment across Europe. This is driving EuropaBio's advocacy across the Biotech Act, EU Inc and other legislations that are building a competitive ecosystem.

Finally, biodefence and biosecurity have emerged within the EU's legislative journey. EuropaBio members already have national and global engagement with these topics and a new Task Force has been established to ensure that EU legislation supports and complements global ambition and maximises EU strength within this critical application.

EU Legislative Frameworks in Biotechnology and Related Fields



Healthcare Biotechnology Council

Mandate and vision

Healthcare biotechnology harnesses the power of biotechnology to advance research and development, manufacturing, and delivery of healthcare solutions that improve patient lives.

The EuropaBio Healthcare Biotechnology Council champions an ecosystem that fosters innovation and unleashes biotechnology's potential as a powerful engine for growth, competitiveness, and resilience across EU countries and regions. This is always with the goal to deliver legislative and regulatory solutions to ensure that patients, societies, and economies benefit from breakthrough biotechnology innovation.

Legislative and regulatory focus

The Council's work focused on the EU's most consequential healthcare legislative files, notably the EU Biotech Act (Part I), the Critical Medicines Act (CMA), and the General Pharmaceutical Legislation (GPL).

Following the publication of Biotech Act Part I in December 2025, the Council coordinated member analysis and alignment to shape EuropaBio's positioning, supported by targeted advocacy activities including engagement with MEPs, coalition partners, and a high level webinar with the European Commission. These efforts were complemented by regular outreach during Strasbourg plenary weeks and a series of policy focused meetings and conferences across Europe.

The General Pharmaceutical Legislation reached political agreement in March 2026, marking a key milestone for healthcare innovation. The Council has since shifted focus to implementation preparedness, engaging with the Commission and the European Medicines Agency on timelines, guidance, and key concepts relevant to healthcare biotechnology, including competitiveness and regulatory predictability.

The Critical Medicines Act progressed into trilogue negotiations, with the Council supporting a targeted advocacy push to ensure supply resilience, access, and security of supply are addressed in a manner fit for biotech innovation. These priorities were reinforced through direct political engagement with key MEPs and cross-industry dialogue platforms.

A secondary priority during the year has been EU-US trade relations and Most-Favoured-Nation considerations, reflecting their strategic relevance for the sector.

Members collaborate through EuropaBio expert groups, including the Biopharmaceutical Strategy, Regulatory Policy, Access and Value, and the OMP/ATMP Working Groups, ensuring aligned expertise and coherent policy positions.

Regulatory engagement and agencies

Regulatory engagement remains a defining strength of the Healthcare Council. As an EMA stakeholder, EuropaBio held its 7th EMA–EuropaBio bilateral meeting in January 2026, bringing together senior representatives from the EMA, the EuropaBio secretariat and member companies, while also participating in the EMA CEO Round Table on 17 April, attended by Director General Claire Skentelbery, and chaired by EMA Executive Director Emer Cooke. Discussions across these engagements covered GPL implementation, the Biotech Act, MDR/IVDR revision, competitiveness, supply chain challenges, and broader perspectives on the EU pharmaceutical system and future regulatory priorities, reinforcing structured dialogue between regulators and healthcare biotechnology stakeholders.

EuropaBio has also strengthened its role within the EU HTA Stakeholder Network, contributing industry expertise to support effective implementation of the HTA Regulation and participating in joint exchanges on practical issues such as horizon scanning for emerging health technologies.

Patients at the centre

Placing patients at the heart of policy discussions remains central to the Healthcare Council's work. Throughout the year, Council activities promoted patient centred approaches across major legislative files, including the Biotech Act, the Critical Medicines Act, and HTA implementation. This commitment has been reflected in senior level participation at rare disease and life sciences events and will be taken forward through preparations for a national level Patient Bio Forum, planned for Q3 2026. The forum will provide a structured multi stakeholder dialogue to connect EU biotech policy with national patient realities and perspectives, supporting more inclusive and informed policymaking.

The voice of EuropaBio in healthcare

EuropaBio's healthcare voice has been active across consultations, alliances, and high level stakeholder engagements throughout the year. A notable highlight was the high level working lunch with the EU Health Coalition in March 2026, offering a platform for open exchange between policymakers, Commission officials, and the biotechnology sector on the Biotech Act.

EuropaBio also strengthened its presence across major international and European conferences, including BIO 2025 in Boston, Advanced Therapies Europe, Life Sciences Baltics, BIO Europe, and the World Orphan Drug Congress, ensuring consistent visibility of healthcare biotech priorities.

Looking ahead to 2027

As major legislative files move from negotiation into implementation, the Healthcare Council will focus on ensuring effective application of the General Pharmaceutical Legislation, continued engagement on the Critical Medicines Act, and sustained advocacy on the EU Biotech Act as negotiations advance.

In parallel, the Council will closely monitor the evolving economic and geopolitical context, recognising its impact on investment, competitiveness, and supply resilience for Europe's healthcare biotechnology sector.

Industrial Biotechnology Council

Mandate and vision

Industrial biotechnology drives Europe's transition to a sustainable, circular and competitive economy. Across sectors, it enables the shift from fossil-based systems to bio-based processes, supports innovation and strengthens resilience, decarbonisation, strategic autonomy and competitiveness.

EuropaBio's Industrial Biotechnology Council plays a pivotal role in advancing Europe's biotech leadership by shaping and enabling policy framework that allows industrial biotechnology and biomanufacturing to scale and reach the market efficiently. It promotes legal clarity, streamlined regulatory pathways and strong conditions for innovation and investment in Europe.

Legislative and regulatory focus

During the reporting period, the Council prioritised strengthening a clear, predictable and efficient regulatory framework that enables the full potential of industrial biotechnology and microorganisms while maintaining high safety standards.

It contributed to key initiatives including the EU Biotech Act, the Food and Feed Safety Omnibus and the Bioeconomy Strategy. A central focus was improving legal clarity for products made with genetically modified microorganisms (GMMs) and an adapted framwork for microorganisms, enhancing predictability for operators and supporting faster market access. The Council also engaged closely with EFSA processes, promoting more efficient procedures and earlier dialogue between applicants and authorities.

In parallel, it followed horizontal files such as the Circular Economy Act, the Industrial Accelerator Act, the Net Zero Industrial Act and the EU Taxonomy, while engaging on sector-specific legislation including the Detergents and Cosmetics Regulations. Throughout the year, the Council advocated for an ambitious Biotech Act placing biomanufacturing at the core of Europe's industrial strategy.

Collaboration and engagement

The Council combines strategic direction with technical expertise, setting priorities and positions while Working Groups and Task Forces provide detailed regulatory input.

This includes dedicated groups on industrial policy, product policy and the Nagoya Protocol, supported by specialised task forces on food-feed and non-food-feed applications and microorganism framework. A cross-cutting Public Affairs Working Group ensures effective advocacy.

The Council works closely with partner associations such as AMFEP and FEFANA and maintains active engagement with European institutions, including the European Commission and Members of the European Parliament. It contributes to key platforms such as the European Bioeconomy Alliance, the Agri-Food Chain Coalition and EBAF, as well as workshops, expert groups and public consultations. Council representatives also participated in key industry and institutional events throughout the year, contributing to policy discussions and visibility.

Key achievements

A key achievement was progress towards greater legal clarity for fermentation-derived products using genetically modified microorganisms, improving predictability for industry.

Developments in EFSA pre-submission advice strengthened early dialogue between applicants and authorities, contributing to more efficient and robust risk assessment processes. The Council also supported initial steps towards an adapted and proportionate regulatory approach for microorganisms, while continuing to advocate for a more fit-for-purpose, product-based framework.

The adoption of the EU Bioeconomy Strategy marked an important milestone, recognising the role of industrial biotechnology and biomanufacturing in driving sustainable growth, industrial decarbonisation and competitiveness. Overall, the year underscored the importance of a coherent, predictable and investment-friendly policy framework to support innovation and scale-up in Europe.

European Forum for Industrial Biotechnology (EFIB)

EFIB by *EuropaBio*

In June 2026, EuropaBio delivered the European Forum for Industrial Biotechnology (EFIB) as part of Bio Innovations Europe in The Hague, convening policymakers, industry leaders, SMEs and investors at a pivotal moment for the European bioeconomy.

The programme included the launch of the 2026 EFIB Statement and high-level discussions on key policy developments, including the Biotech Act, the Food and Feed Safety Omnibus and the Bioeconomy Strategy, alongside dedicated SME and executive roundtable sessions. EFIB reinforces EuropaBio's role as a key convenor and policy shaper.

Looking ahead to 2027

Looking ahead, the Council will focus on ensuring that key legislative initiatives, including the Biotech Act and the Food and Feed Safety Omnibus, deliver clear, workable and consistently implementable outcomes across Member States, avoiding fragmentation and ensuring a level playing field.

It will remain closely engaged in the implementation of the Bioeconomy Strategy and broader industrial policy developments, with continued emphasis on regulatory clarity, coherence and support for innovation, investment and scale-up in Europe.

National Associations Council & SME Platform

Mandate and vision

The National Associations Council (NAC) is EuropaBio's network of national and regional biotechnology associations.

Over the past year, the Council welcomed seven new members, bringing total membership to 32 associations across Europe, covering the healthcare, industrial and agri-food sectors. New members include the UK's Bio-Based and Biodegradable Industries Association, Biotech Austria, Dansk Biotek, the Hungarian Biotechnology Association, Slovenia Biotech Hills, the Association of Biopharmaceutical Manufacturers in Latvia, and the Luxembourg Institute of Science and Technology - further consolidating its position as the largest network of its kind in Europe.

The NAC's mandate is to support the creation, growth and uptake of biotechnology innovation across Europe by aligning national priorities, strengthening coordinated advocacy at European level, and raising the sector's visibility with policymakers and the public.

In practice, this involves convening national ecosystems to exchange intelligence and coordinate positions on cross-sector policy files; delivering public-facing campaigns, including European Biotech Week; engaging national and EU policymakers to keep biotechnology high on the political agenda; and drawing on innovators' experience to shape evidence-based policy proposals. Together, these efforts support a globally competitive biotech sector contributing to a more sustainable, healthier and prosperous Europe.

Complementing the NAC, the SME Platform brings together biotechnology SMEs, start-ups and scale-ups, ensuring that entrepreneurial perspectives and on-the-ground challenges inform EuropaBio's advocacy and policy priorities.

At the global level, the NAC participates in the International Council of Biotechnology Associations (ICBA), helping ensure that European priorities are represented in international discussions.

Legislative and regulatory focus

In 2025–26, the NAC and SME Platform drove a broad policy agenda across the full biotech value chain, with the development of a strong and bold EU Biotech Act as the central priority.

The NAC led advocacy on key cross-cutting files, including the Multiannual Financial Framework (MFF), European Competitiveness Fund (ECF), Capital Markets Union, the European Innovation Act, and EU-INC. It also contributed its national expertise to sectoral files, such as the Critical Medicines Act, General Pharmaceutical Legislation, and the Food and Feed Safety Omnibus.

The SME Platform played a central role in shaping start-up and scale-up policy, particularly through its work on EU-INC and the Biotech Act. Improving access to finance and reducing barriers to growth remained key priorities, while its expanding membership also informed discussions on biosecurity and dual-use applications.

Engagements and publications

The NAC's flexible structure, combining working groups, task forces, and ad hoc coordination, enabled timely contributions across multiple policy files.

Throughout the year, the Secretariat and member associations represented EuropaBio at national and European events, while targeted workshops supported engagement with the Biotech Act. International participation in the BIO Convention in San Diego continued to grow, while BIO-Europe Spring in Lisbon further strengthened its role as a leading forum connecting industry, policymakers, and investors.

The SME Platform complemented this with a webinar series on biotech financing, bringing together investors, founders, and public institutions, including the European Investment Bank.

The voice of EuropaBio for national biotechnology

NAC members engaged with national governments, MEPs, and the European Commission to ensure that policy proposals reflect national realities, including through participation in Commission workshops on financing, skills, cluster development, and biosecurity, as well as contributions to the European Innovation Act and EU-INC.

The SME Platform represented entrepreneurial perspectives in policy discussions, including at the Bruegel event on a unified EU startup framework, and highlighted the barriers faced by biotech founders. These efforts resulted in consultation responses and position papers on key files, including the MFF, ECF, EU-INC, and the Biotech Act, and in additional recognition through contributions to OECD work on biotechnology, foreign investment, and SME linkages.

Looking ahead to 2027

Looking ahead, the NAC and SME Platform will focus on delivering an ambitious EU Biotech Act, alongside continued work on the European Innovation Act and EU-INC. Biosecurity and biodefence will become a dedicated priority through a new Task Force led by the NAC and its Chair, Dr Ricardo Gent, with strong input from SME members active in dual-use technologies.

Institutional engagement will centre on key political milestones, including upcoming EU Council Presidencies and the eighth Council Presidency Summit at the European Parliament. Public engagement will continue through initiatives such as the 14th edition of Biotech Week and participation in major international events.

For the SME Platform, priorities remain improving financing conditions and supporting company creation and scale-up, alongside continued engagement on the European Innovation Act to ensure SME perspectives remain central to EU policy.

Together, the NAC and SME Platform enter the next phase with a strengthened network, a clear policy agenda, and a shared ambition to position Europe as a global leader in biotechnology innovation.

Biomanufacturing Platform

Vision, engagement, leadership

EuropaBio's Biomanufacturing Platform continues to bring EU focus towards biomanufacturing by convening policymakers, industry and stakeholders through high-level events. These meetings provide a trusted forum to discuss how Europe can translate ambition into impact, particularly through legislation that strengthens competitiveness, resilience and sustainability across all sectors.

Biotech & Biomanufacturing Summit 2025

In October 2025, the Platform hosted its third Biotech & Biomanufacturing Policy Summit, bringing together over 130 stakeholders from across EuropaBio membership, the European Commission, Permanent Representations to the EU and the European Parliament.

In the run up to the adoption of the EU Biotech Act Part I, the Summit focused on Europe's ambition for biotechnology and biomanufacturing and the policy frameworks required to deliver innovation into the market at scale.

Panel discussions explored three core themes:

- Enabling EU markets for biotech products
- Enhancing access through effective market pathways
- Building a strong EU ecosystem supported by skills, finance and infrastructure.

Biomanufacturing Policy Summit 2026

On July 1st 2026, EuropaBio hosted its fourth Biomanufacturing Policy Summit.
As we travel towards the mid-point in the current legislative mandate, the Summit focussed on three main questions for discussion across participants from all sectors where biomanufacturing is integral for modernisation and competitiveness:

- What has been achieved for biomanufacturing through legislation to date?
- Where do legislative gaps remain?
- How do we address these gaps within the current mandate and geopolitical context, and look ahead beyond 2029?

The Summit also previewed the 2026 update of the EuropaBio–WifOR study 'Measuring the Economic Footprint of the Biotechnology Industry in the European Union' ahead of the full report launch in September.

Looking ahead – increased focus on advocacy

The Biomanufacturing Platform continues to grow in significance for EuropaBio, Members and effective policy. As Biotech Act Part II and other legislations are adopted and travel to completion, the Platform will play a clearer role in addressing policy priorities that do not fall within the three Councils. It will engage biomanufacturing experts from across members and ensure the precision and depth of advocacy required for the full manufacturing value chain.

EU Projects

EuropaBio is part of two Horizon Europe projects, PRIMED and APROVALS, and joined the Coordination and Support Action BIOLEAD in June 2026. Together, these initiatives promote innovation, industrial deployment and regulatory alignment across biotech, while reinforcing EuropaBio's advocacy priorities and stakeholder engagement.

PRIMED Project

PRIMED – Redesigning the Primary Sector for Maximizing Bioeconomy Development – supports the development of sustainable, regionally anchored bio-based value chains through five regional Living Labs and multi-actor collaboration. It combines technical demonstrations with ecosystem building and policy analysis to enable the scale-up of circular bioeconomy solutions.

EuropaBio leads policy and framework analysis, identifying regulatory, investment and supply chain challenges, and translating project insights into recommendations for European and national policymakers, while connecting innovation with market needs through its membership. *Project number 101135353*.

APROVALS Project

APROVALS – Accelerating Proteins Innovators Beyond Regulatory Sandboxes – supports innovators in cellular agriculture and novel protein technologies through a collaborative testing environment addressing technical, regulatory and market challenges.
EuropaBio coordinates stakeholder engagement, ensuring policy alignment and contributing regulatory expertise to translate project outcomes into actionable insights. *Project number 101158173*.

Accelerating PROteins innoVAtors beyond reguLatory Sandboxes

BIOLEAD Project

BIOLEAD, launched in June 2026, aims to strengthen Europe's leadership in biotechnology and biomanufacturing by delivering a practical roadmap in support of the EU Biotech Act and Bioeconomy Strategy. It provides evidence and policy recommendations to accelerate the scale-up and uptake of bio-based solutions within a more innovation-friendly regulatory and investment framework. *Proposal number 101291461*.

These projects reinforce EuropaBio's role at the interface of policy, industry and innovation, while supporting a competitive and sustainable European bioeconomy.

Communicating Biotechnology

Positioning Biotechnology at Europe's Strategic Core

EuropaBio works to strengthen visibility and recognition of biotechnology and biomanufacturing as essential contributors to Europe's competitiveness, sustainability and innovation ambitions.

Throughout the year, communications were closely aligned with key EU policy developments, ensuring that biotechnology remained visible and well understood at critical moments in the legislative cycle.

A central focus was the European Commission's proposal for a Biotech Act, published on 16 December 2025. EuropaBio supported awareness and engagement around the proposal through targeted communications and stakeholder outreach, including a high-level webinar with Director-General Sandra Gallina (DG SANTE) and a series of educational LinkedIn posts on the Biotech Act (Parts I and II), helping to explain its objectives and implications in a clear and accessible way.

EuropaBio also supported joint industry advocacy, bringing together over 40 European, national and regional organisations in a common call for a Biotech Act II dedicated to biomanufacturing. This initiative highlighted the importance of scaling innovation and ensuring that Europe's scientific excellence translates into industrial strength and market delivery.

Communications further supported EuropaBio's engagement on the European Commission's Food & Feed Safety Simplification Package, positioning it as an important step towards improving regulatory clarity, reducing administrative burden and enabling innovation across the value chain.

Campaigns, events and stakeholder engagement

Alongside policy engagement, EuropaBio continued to highlight the real-world impact of biotechnology through targeted campaigns and outreach activities. Content developed around key international moments, including World Cancer Day and Rare Disease Day, demonstrated the contribution of biotechnology to healthcare innovation and improved patient outcomes.

European Biotech Week remained a flagship initiative, bringing together events and activities across Europe to celebrate biotechnology and its applications. Supported by members and partners at national and local levels, it raises awareness of the role of biotechnology in health, sustainability and economic growth, and its relevance to everyday life.

Through a combination of policy communications, campaigns and events, EuropaBio strengthened its role as a trusted voice within the European biotechnology ecosystem, connecting stakeholders and supporting a shared understanding of the value of biotechnology for Europe and beyond.

European Biotech Week

Innovation is in our Genes

by EuropaBio

To keep up to date with all our activities, follow us on LinkedIn

linkedin.com/company/europabio/

EuropaBio in Partnership

European Bioeconomy Alliance (EUBA)

EuropaBio is a founding member of EUBA, contributing to joint efforts to promote the role of the bioeconomy in Europe. Through EUBA, EuropaBio supports engagement with policymakers and stakeholders, helping to raise awareness of the benefits of bio-based solutions and fostering a more favourable framework for their deployment.

bioeconomyalliance.eu

BIO Convention

EuropaBio represents Europe at the BIO International Convention, the world's leading biotechnology event. Together with National Associations, member companies and EU institutions, it supports European visibility through SME delegations, national pavilions and high-level sessions, fostering global collaboration, investment and growth across the biotech ecosystem.

convention.bio.org

The International Council of Biotechnology Associations (ICBA)

EuropaBio contributes to the ICBA, a global alliance of biotech associations, strengthening the international voice of the sector. Through its leadership role, it supports policies that foster innovation and resilience across health, agriculture, industrial and environmental biotechnology, enabling sustainable growth of national and global biotech ecosystems.

internationalbiotech.org

Agri-Food Chain Coalition

EuropaBio is a member of the Agri-Food Chain Coalition, which brings together stakeholders across the agri-food value chain to address cross sectoral challenges. EuropaBio contributes to joint statements and selected activities, supporting discussions on topics such as innovation in the agri-food space and broader policy developments relevant to biotechnology.

agrifoodchaincoalition.eu

Business at OECD

EuropaBio engages with Business at OECD to contribute industry perspectives on biotechnology policy and regulatory frameworks. Its participation supports international dialogue on innovation, including engagement in OECD initiatives such as the Global Forum on Technology, promoting a sustainable and innovation-driven global bioeconomy.

businessatoecd.org

European Commission Industrial Forum

EuropaBio is represented in the European Commission's Industrial Forum 2.0, launched in 2026. It contributes to discussions on industrial competitiveness and transition pathways, representing biotechnology and biomanufacturing across sectors and ecosystems, and promoting biotech as a key enabler of Europe's green and digital industrial transformation.

ec.europa.eu

Innovative Health Initiative (IHI)

EuropaBio is an industry partner in the Innovative Health Initiative, advancing collaborative research on priority health challenges. Representing biotechnology, it contributes to cross-sector projects addressing pre-competitive topics, supporting innovation in healthcare delivery and reinforcing Europe's global leadership in health research and innovation.

ihi.europa.eu

Rare Disease Moonshot

A founding member of the Rare Disease Moonshot, EuropaBio supports collaboration to accelerate research and development for rare and paediatric diseases. It contributes industry expertise to advance scientific discovery, therapeutic innovation and policy solutions addressing unmet medical needs.

rarediseasemoonshot.eu

Joint Industrial Cooperation Forum (JICF)

EuropaBio participates in the Joint Industrial Cooperation Forum, supporting coordination across health-related industrial ecosystems for crisis preparedness and response. It contributes to policy discussions and promotes recognition of biotechnology as a key component of Europe's capacity to respond to and manage health emergencies.

health.ec.europa.eu

European Board on Agriculture and Food (EBAF)

EuropaBio is a member of the European Board on Agriculture and Food, an expert group established in 2025 following the Strategic Dialogue on Agriculture. It represents innovation across the agri-food value chain, contributing expertise to support a competitive, sustainable and resilient European food system.

agriculture.ec.europa.eu

EU Health Coalition

EuropaBio is a member of the EU Health Coalition, working with stakeholders across the health ecosystem to promote a healthier Europe. It supports advocacy efforts highlighting the strategic importance of life sciences and health innovation for Europe's competitiveness, resilience and societal well-being.

euhealthcoalition.eu

EuropaBio Members

Corporate Members

Associate Members

21st BIO

ABOLIS BIO-SYNTHESIS ARCHITECTS

BBIA CHAMPIONING THE INDUSTRIAL BIOECONOMY

Bio Base Europe Pilot Plant

BIOSAFE

CRYSTALS FIRST TURNING INSIGHTS INTO MEDICINES

cytiva

disc medicine

DNASCRIPT

ENDURO

EUCROF European CRO Federation

Formo

FRÉGET GLASER & ASSOCIÉS

GOURMEY

GRITTGENE THERAPEUTICS

Hawkwood

kintiga

LUXEMBOURG INSTITUTE OF SCIENCE AND TECHNOLOGY LIST

nibrt National Institute for Bioprocessing Research and Training

niconex medical Crafting Elegant Precision

Phytolon Natural Food Colors

probiotic Group

R+ regenold Development Regulatory Market Access

Ribbon BIO

roebling

shakeup factory

SICOS LA VOIX DES INDUSTRIES CHIMIE FINE ET BIOTECH

Solutions For Life sciences SFL A VERISTAT COMPANY

STANDING OVATION

Syneos Health Communications

TECHNOVATIVE SOLUTIONS

EST. 2022 VERLEY LYON, FRANCE

VINTURA a cencora company

VCLS Voisin Consulting Life Sciences

WHC Lab

BCG

National Associations & BioRegions

To find out more about how to join EuropaBio, visit our membership page
europabio.org/become-a-member/

Become Part of EuropaBio

EuropaBio welcomes Members from across the biotechnology ecosystem, working together to grow and champion the biotechnology sector in Europe.

Who are EuropaBio Members?

EuropaBio Members represent the spectrum of biotechnology activities in Europe and beyond. From pre-market SMEs through to global multinationals in all sectors, plus their regional and national associations, EuropaBio Members are the fabric of the sector.
Member Companies and associations are active in all sectors and applications of biotechnology, including:

- Developers of biotechnology products
- Application of biotechnology within manufacturing process
- Provision of biomanufacturing services and capacity
- Expert service provision across the innovation pathway and value chain of sectors

Membership benefits

Join the EuropaBio community and be the future of European biotechnology.

Be informed:

- Detailed information on legislative and regulatory frameworks
- Expert analysis at national, EU and global levels

Be involved:

- Set priorities for biotechnology advocacy through Councils for Healthcare, Industrial Biotechnology and National Associations
- Participate in working groups and task forces across public affairs and regulatory priorities

Be the voice for biotechnology:

- Showcase your technology, business and community for biotechnology in action
- Engage with policymakers, regulators, investors and more to demonstrate the pathway for biotechnology

To find out more about how to join EuropaBio, visit our membership page
europabio.org/become-a-member/

EuropaBio®
The European Association for Bioindustries

europabio.org

EuropaBio AISBL, Avenue des Arts 53, b. 8, 1000 Brussels, Belgium
www.europabio.org | VAT: BE 0477.520.310 - RPM Bruxelles | Transparency Register: 1298286943-59